The incidence of many cancers located in the liver, lungs, kidneys and bones continues to increase each year. Surgical resection of many of these tumors is the referenced standard treatment to excise, or remove the tumor and the surrounding tissue that may contain tumor cells. While surgery has proven to be effective in cancer treatment and remains the gold standard, it is not a treatment option for all patients. Between 60% and 80% of patients are not surgical candidates as determined by the surgeon due to the extent and location of the tumor(s) or other co-existing factors.

New therapies and technologies are being used by physicians to treat these non-surgical patients. These may include thermal ablation (heating or freezing the tumor), intra-arterial therapies such as chemoembolization or radioembolization, new tumor specific biologics and improvements to other non-invasive procedures such as radiation therapy or focused ultrasound. INTIO is positioned to INTegrate the imaging needs for all of these therapies from procedural planning through treatment and follow-up.

INTIO has created solutions for critical clinical needs of the Interventional Oncologist. Through advanced segmentation technology the tumor is identified from diagnostic CT scans and deformably registered into the procedural CT scan. This enables the tumor to be visualized during the ablation procedure in 3D and allows the interventionalist to achieve the desired position of the applicators relative to the position of the tumor. Once the thermal ablation has commenced INTIO’s software provides an ability to monitor the change in tissue in real time providing feedback on the status of the tumor undergoing ablation. Current tools do not provide for this real-time monitoring and may result in incomplete ablation zones due to inadequate heating.

As new cancer treatments emerge, INTIO is poised to enable many of the technologies and integrate the imaging for clear visualization.